These medications support weight loss and blood sugar regulation, which makes them very appealing to patients with coexisting illnesses
About 26% discontinued GLP-1 therapy over three years, and another 23% had interruptions in treatment
10.1007/s10555-024-10192-9 32 IwamotoY.KimuraT.DanK.IwamotoH.SanadaJ.FushimiY.et al (2024)
Canagliflozin has been trialed in a phase IIb study in overweight and obese subjects without T2D
This timing may be influenced by the enhanced endogenous secretion of GLP-1RAs following surgery, which has been shown to contribute to appetite management, insulin secretion, and WL [74,75,76]
Theres also a similar class of medications called dual GLP-1 and GIP receptor agonists, and tirzepatide (the generic name for Mounjaro and Zepbound) is the only drug available in the U.S